3 Of The Best Growth Stocks To Buy In October 2026

Amazon

Despite being a leader in the tech sector and having a high valuation of around $2.8 trillion in market cap, I still think Amazon’s stock may be due for more of a rally than it’s been on of late. This year, its s are up just 11%, trailing the S&P 500’s gains of around 14%.

Its valuation, however, isn’t all that high, as its price-to-earnings (P/E) multiple is only 20. While investment gains did recently pad its earnings numbers, this is a fairly low multiple to be paying for Amazon stock, which in previous years traded at far larger premiums.

Expand

NASDAQ: AMZN

Amazon

Premium Feature

Moneyball Superscore

90/100

Today’s Change

(1.58%) $3.97

Current Price

$255.37

Key Data Points

Market Cap

$2.7TMarket cap calculated using publicly traded s outstanding only. Does not include unlisted, private, or dual-class non-traded s. Implied market cap may vary.

Day’s Range

$251.08 – $256.22

52wk Range

$196.00 – $287.20

Volume

17.8M

Avg Vol

39.2M

Gross Margin

50.77%

The company is also investing heavily in artificial intelligence (AI), developing its own chips, and it has a robotaxi business in Zoox that’s still in its early stages.

Although I wouldn’t call the tech giant underrated, I do think the market isn’t valuing it appropriately. There could be a fair bit of upside for investors who buy Amazon stock today, which is why it’s on this list. It’s not a risky business to invest in, and its relatively low valuation makes it a great buy.

AbbVie

Another attractive option for growth-oriented investors is AbbVie, a major player in the healthcare sector. What I about its business is not only how adaptable it is, but also how well diversified its operations are.

Expand

NYSE: ABBV

AbbVie

Premium Feature

Moneyball Superscore

80/100

Today’s Change

(0.45%) $1.20

Current Price

$266.96

Key Data Points

Market Cap

$470BMarket cap calculated using publicly traded s outstanding only. Does not include unlisted, private, or dual-class non-traded s. Implied market cap may vary.

Day’s Range

$260.62 – $268.86

52wk Range

$190.75 – $269.39

Volume

1.6M

Avg Vol

5M

Gross Margin

71.42%

Dividend Yield

2.57%

This is a stock that investors were worried about in the past due to patent expirations on its leading drug, Humira. Well, AbbVie has done just fine as Rinvoq and Skyrizi have made up for Humira’s loss in revenue. AbbVie has been busy with acquisitions in growing its business, but unfortunately, acquisition-related expenses have weighed on its bottom line.

Thus, the healthcare stock can appear to be much more expensive than it really is if investors are focusing on the trailing P/E multiple of 75. The forward P/E multiple, which is based on analyst expectations of future earnings, is much more reliable in this case. At a forward P/E of just 16, AbbVie’s stock suddenly looks cheap, as the S&P 500 average is a forward P/E of around 20.

Netflix

Yet another cheap-looking stock to buy in October is Netflix. It’s down an incredible 27% this year. Despite posting double-digit growth and its earnings numbers still looking strong, investors have nonetheless remained bearish on the streaming stock.

The market appears to be pricing in the risk and uncertainty about its future growth prospects. Netflix’s name has come up in acquisition rumors, and there have been concerns that its customers aren’t highly engaged, ditching shows due to long gaps between seasons.

These concerns, however, aren’t translating into the financials. In its most recent quarter, Netflix’s revenue rose by 13%, with the company still projecting at least $51 billion in revenue for the full year — that represents a year-over-year increase that’s also around 13%.

Expand

NASDAQ: NFLX

Netflix

Premium Feature

Moneyball Superscore

81/100

Today’s Change

(0.61%) $0.42

Current Price

$67.92

Key Data Points

Market Cap

$281BMarket cap calculated using publicly traded s outstanding only. Does not include unlisted, private, or dual-class non-traded s. Implied market cap may vary.

Day’s Range

$67.31 – $68.50

52wk Range

$65.08 – $124.86

Volume

18.6M

Avg Vol

37.1M

Gross Margin

49.53%

Ultimately, Netflix is still doing a good job of keeping its customers subscribed, and that’s evident with its sales remaining strong. The company doesn’t lock customers into long-term agreements, so any problems would be quick to show up on quarterly earnings reports. Its growth is slowing, and that’s not surprising given the size of the business, but it’s not a sharp decline by any stretch.

At 22 times trailing earnings and a forward P/E of 19, Netflix is another incredibly attractive growth stock to buy right now. The stock’s sell-off doesn’t appear warranted.

Read Next

Oct 6, 2026 •By Leo Sun

History Says Infrastructure Booms Create Winners and Losers. Here Are 3 AI Cloud Stocks to Watch.

Oct 6, 2026 •By Brett Schafer

Not Microsoft. Not Google. Analysts Call This $2.7 Trillion Tech Titan the Most Undervalued AI Play.

Oct 6, 2026 •By Jeremy Bowman

Best AI Stocks to Buy in 2026 and How to Invest in Them

Oct 6, 2026 •By Scott Levine

6 Best Drone Stocks for 2026 and How to Invest

Oct 6, 2026 •By Adria Cimino

If I Could Only Buy One AI Stock Before 2027, It Would Be This One

Oct 5, 2026 •By Lyle Daly

The Magnificent Seven Stocks: Market Cap, S&P 500 Weight, and Returns

About the Author

David Jagielski, CPA, has been a contributing Motley Fool stock market analyst covering healthcare, consumer staples, consumer discretionary, and technology stocks since 2017. David has more than 10 years of experience in finance roles across businesses of different sizes and sectors. He holds a Certified Public Accountant designation in Canada.

TMFdjagielski

Stocks Mentioned

Motley Fool Stock Advisor’s Latest Pick

Get Access

—% Avg Return

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.